期刊文献+

慢性丙型肝炎及其抗病毒治疗进展 被引量:10

Advances in antiviral therapy for chronic hepatitis C
原文传递
导出
摘要 自20世纪70年代提出了输血后非甲非乙型肝炎之后直至1989年才应用现代分子克隆技术鉴定出丙型肝炎病毒(HCV),并证实HCV是输血后肝炎的主要致病因子。相对乙型肝炎,丙型肝炎更容易慢性化,导致肝硬化和肝细胞肝癌,治疗更困难,至今尚无有效疫苗预防。因此丙型肝炎是世界主要公共卫生问题之一。随着对丙肝病毒研究及认识的加深,目前抗丙肝病毒药物的研发进入了突破阶段,已经有多个新机制的药物获准上市,还有较多的新药进入了临床试验阶段。本文对丙肝流行病学、治疗学进行了回顾,对新药研发及目前上市的新药进行了归纳。 Non-A,non-B post-transfusion hepatitis was proposed in the 1970 s,but until 1989,hepatitis C virus( HCV) was identified and confirmed as the main pathogenic factor of post transfusion hepatitis by application of modern molecular cloning technologies. Compared with hepatitis B,hepatitis C is not only liable to become chronical and,easier to progress to cirrhosis and hepatocellular carcinoma( HCC),but also more difficult to treat. Moreover,there is no effective vaccine for HCV. Therefore,hepatitis C is one of the major public health problems in the world. With the advancing of research and understanding of hepatitis C virus,the research and development of drugs directly agaist HCV are currently close to a breakthrough. At present,many new drugs with multiple mechanisms have been approved,and more and more others candidates are entering clinical trials. This article reviews the epidemiology and therapy about HCV,and offers information on drugs currently under investigation and drugs already on the market.
出处 《中国新药杂志》 CAS CSCD 北大核心 2015年第19期2209-2213,共5页 Chinese Journal of New Drugs
关键词 慢性丙型病毒性肝炎 丙型肝炎病毒 抗病毒治疗 药物研发 chronic hepatitis C hepatitis C virus antiviral therapy drug research and development
  • 相关文献

参考文献14

  • 1World Health Organization ( WHO ). Hepatitis C [ EB/OL]. (2012 -07 ). http://www, who. int/mediacentre/factsheets/ fs164/en/.
  • 2FREEMAN RB, STEFFICK DE, GUIDINGER MK, et al. Liver and intestine transplantation in the United States 1997 - 2006 [J]. Am J Transplant,2008,8(4Pt2) :958 -976.
  • 3DAVILA JA, MORGAN RO, SHAIB Y,et al. Hepatitis C Infec- tion and the increasing incidence of hepatocellular carcinoma: a population-based study [ J ]. Gastroenterology, 2004, 127 ( 5 ) : 1372 - 1380.
  • 4TAO QM,WANG Y, WANG H,et al. Seroepidemiology of HCV and HBV infection in northern China[ J ]. Gastroenterologia Ja- ponica, 1991,26 ( Suppl 3 ) : S156 - S158.
  • 5Expert Committee on Chronic Hepatitis C Antiviral Therapy. Ex- pert consensus for antiviral therapy for chronic hepatitis C [ J ]. Chin J ExpClin Infect Dis ( Electronic Edition ), 2009,3 ( 3 ) : 343 - 352.
  • 6赵树铭,蒋天伦,黎儒青,GAO Feng-Xiang,LU Ling,ZHENG Hao-Qiang,胡建,范娅涵,李兵,肖瑞卿,Yury Khudoyakov.重庆地区无偿献血者丙肝病毒感染及对献血者招募的影响(英文)[J].中国实验血液学杂志,2008,16(3):676-680. 被引量:10
  • 7丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:735
  • 8谢尧,范小玲,杨松.慢性丙型肝炎抗病毒治疗专家共识[J].中华实验和临床感染病杂志(电子版),2009,3(3):59-64. 被引量:67
  • 9FDA. Label approved on 07/28/2014 for VICTRELIS [ EB/OL]. (2014 -07 -28 ). http ://www. accessdata, fda. gov/drugsatfda_ does/label/2014/202258 sO15 lbl. pdf.
  • 10FDA. Label approved on 10/28/2013 for INCIVEK[ EB/OL]. (2013 -10 -28 ). http ://www. aecessdata, fda. gov/drugsatfda_ docs/label/2013/201917 s0121b1. pdf.

二级参考文献32

  • 1丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:735
  • 2孔令魁,周一炎,朱为刚.血源转换前后招募的有偿和无偿献血人群风险评估[J].临床输血与检验,2005,7(4):252-254. 被引量:2
  • 3孟忠华,杨劲,周华平,严力行.浙江省献血者HIV感染率的11年回顾性调查[J].中国实验血液学杂志,2006,14(6):1231-1233. 被引量:8
  • 4Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non- responders to interferon monotherapy: a meta- analysis of individual patient data[ J ]. Gut, 2002,51:864-869.
  • 5Papatheodoridis GV, Papadimitropoulos VC, Hsdziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus- reated cirrhosis: a meta- analysis[J] .Aliment Pnarmaool Ther, 2001,15:689- 698.
  • 6Kjaergard LL, Krogsgaard K, Gluud C. Interfern alfa with or without ribavirin for chronic hepatitis C: systematic review of randonmised trials[J].BMJ, 2001,323:1151 - 1155.
  • 7Alberti A, Benvegnu L. Management of hepatitis[J] .J Hepatol, 2003,38(Suppl1): S1014 - S1 18.
  • 8Poynard T, MdHutchison J, Davis GL, et al. Impact of interferon alfa - 2b and ribavirin on progression of liver fibrosiis in patients with chronic hepatitis C[J].Hepatology, 2000,32:1131 - 1137.
  • 9Booth JCL, O' Grady J, Neuberger J. Clinical guidelines on the mangement of hepatitis C[J]. Gut, 2001, 49(Suppl I ): il - i12.
  • 10Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systemic review[J]. Hepatology, 2002, 36(5 Suppl 1 ):S135 - S144.

共引文献801

同被引文献79

引证文献10

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部